Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer

BACKGROUND: Cetuximab is often administered to patients with KRAS wild-type (KRAS-WT) metastatic colorectal cancer (mCRC), although resistance inevitably develops. We hypothesized that co-inhibition of the epidermal growth factor receptor (EGFR) with cetuximab and downstream cyclin-dependent kinases...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorah, Jonathan D, Moore, Dominic T, Reilley, Matthew J, Salem, Mohamed E, Triglianos, Tammy, Sanoff, Hanna K, McRee, Autumn J, Lee, Michael S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249423/
https://www.ncbi.nlm.nih.gov/pubmed/36288238
http://dx.doi.org/10.1093/oncolo/oyac222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249423/
https://www.ncbi.nlm.nih.gov/pubmed/36288238
http://dx.doi.org/10.1093/oncolo/oyac222

Ejemplares similares